富含白的重复蛋白质复合物激活蚊子补充剂,以防范菌寄生虫
Michael Povelones1, Robert M Waterhouse, Fotis C Kafatos
1Division of Cell and Molecular Biology, Department of Life Sciences, Imperial College London, Exhibition Road, London SW7 2AZ, UK.
概括
两种蚊子蛋白,LRIM1和APL1C,形成一个复合体,针对疟疾寄生虫进行破坏. 这一发现有助于我们更好地了解Anopheles gambiae等疾病载体的先天免疫力.
科学领域:
- 免疫学 免疫学 免疫学
- 昆虫学 昆虫学是一门学科.
- 寄生虫学的寄生虫学
背景情况:
- 富含白的重复含有蛋白质对于各种生物体的宿主防御至关重要.
- 像Anopheles gambiae这样的蚊子是人类重大病原体的载体,包括疟疾寄生虫.
研究的目的:
- 调查丰富于白的重复含有蛋白质 (LRIM1和APL1C) 在阿诺菲莱斯甘比亚对疟疾免疫力的作用.
- 阐明这些蛋白质与其他免疫元件相互作用以消除虫寄生虫的机制.
主要方法:
- 蛋白质组分析以确定Anopheles gambiae hemolymph中的蛋白质复合体.
- 生物化学试验用于研究蛋白质相互作用和二硫化物桥梁形成.
- 使用Plasmodium berghei的功能测试来评估寄生虫的向和破坏.
主要成果:
- LRIM1和APL1C形成了一个高分子量复合体,由蚊子血淋巴中的二硫化物键稳定.
- 这种复合物与补充C3样蛋白TEP1相互作用,影响其活性.
- LRIM1-APL1C-TEP1相互作用导致TEP1在Plasmodium berghei寄生虫的局部化,标记它们进行破坏.
结论:
- LRIM1-APL1C复合体是Anopheles gambiae对疟疾的天生的免疫反应的关键组成部分.
- 这种蛋白质复合物与TEP1一起,提供了对中肠入侵的Plasmodium寄生虫的重要防御机制.
- 其他载体蚊子中LRIM1和APL1C的正义学说表明,它们在病原体防御中起着保留的作用.
相关概念视频
Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
Symbiosis
Symbiotic relationships are long-term, close interactions between individuals of different species that affect the distribution and abundance of those species. When a relationship is beneficial to both species, this is called mutualism. When the relationship is beneficial to one species but neither beneficial nor harmful to the other species, this is called commensalism. When one organism is harmed to benefit another, the relationship is known as parasitism. These types of relationships often...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...


